News
Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval. Biogen said it terminated a ...
Biogen is pulling the plug on the controversial drug Aduhelm, the first drug cleared by government health officials for treating Alzheimer's in nearly two decades. The pharmaceutical giant is ...
Biogen signs lease for Kendall Common as part ... footprint New building will be designed to foster collaboration and spark innovation; Biogen plans to relocate Cambridge-based employees to ...
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results